TrialInvestigational new drugs2014

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.

Yohann Loriot et al.PubMed ↗Publisher ↗

No numbers read from the abstract.